CollPlant develops, manufactures and commercializes products for tissue repair and organ manufacturing from rhCollagen.

November 13, 2017 | Israeli regenerative medicine company Collplant has raised about $7.4 million in private placement due to a number of filings submitted by the company to the Tel Aviv Stock Exchange over the past three months, according to a report in Calcalist. In November, the Ness Ziona-based company announced a private placement agreement […]

April 2, 2017| Israeli biomed company CollPlant, a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, “rhCollagen”), has just provided a commercial and operational update in its annual reports. The company has progressed to the commercial stage with the signing of Vergenix™FG and Vergenix™STR distribution and sales agreements in Europe. […]

The company is using tobacco plants to create human cells to test the Zmapp Ebola vaccine, currently the best treatment for Ebola.